Allorecognition and Allosensitization

Allorecognition is the process by which the recipient immune system recognizes donor histocompatibility antigens as foreign, the molecular starting point of the alloimmune response. Allosensitization is the prior priming of that response, when earlier exposure to foreign HLA, through pregnancy, transfusion, or a previous transplant, generates memory and donor-specific antibodies that raise the risk of rejection.

Definition

Allorecognition is the recognition of non-self histocompatibility antigens by recipient T cells, occurring through the direct pathway (recipient T cells engaging intact donor MHC on donor cells) and the indirect pathway (recipient antigen-presenting cells presenting processed donor peptides); allosensitization is the pre-existing alloimmune priming, including donor-specific antibodies, that results from prior antigen exposure.

Scope

This entry covers the immunological concepts underlying rejection rather than a clinical disease: the direct and indirect pathways of allorecognition, the role of HLA as the dominant alloantigen, and how sensitization is detected through antibody testing and crossmatching. It is a reference and educational description and not clinical guidance.

Core questions

• How do the direct and indirect pathways of allorecognition differ?
• Why are HLA molecules the principal targets of the alloimmune response?
• How does prior sensitization change a recipient's transplant risk, and how is it measured?

Key concepts

• Human leukocyte antigen (HLA) / MHC
• Direct allorecognition
• Indirect allorecognition
• Allosensitization (pregnancy, transfusion, prior transplant)
• Donor-specific antibodies
• Panel-reactive antibody and calculated PRA
• Crossmatching
• Memory alloresponse

Key theories

Direct and indirect allorecognition

Recipient T cells can recognize donor antigen in two ways: directly, by engaging intact donor MHC molecules displayed on donor cells, or indirectly, by recognizing donor-derived peptides processed and presented on recipient antigen-presenting cells; the two pathways differ in tempo and are linked to different forms of rejection.

Mechanisms

In direct allorecognition, recipient T cells bind intact donor MHC molecules on donor antigen-presenting cells carried within the graft, producing a strong early response. In indirect allorecognition, donor antigens are taken up, processed, and presented as peptides by the recipient's own antigen-presenting cells, sustaining the response over the longer term and providing help for antibody production. Allosensitization occurs when earlier exposure to foreign HLA generates memory T and B cells and donor-specific antibodies, so that a subsequent graft bearing the same antigens meets an accelerated, antibody-capable response. Sensitization is assessed by screening for and characterizing HLA antibodies and by crossmatching donor and recipient.

Clinical relevance

Understanding allorecognition explains why HLA matching and immunosuppression are central to transplantation, and characterizing sensitization through antibody testing and crossmatch underlies histocompatibility assessment and the interpretation of immunological risk in transplant studies. This entry describes concepts and evidence and does not provide individualized clinical recommendations.

Epidemiology

Sensitization is more common in recipients with prior pregnancies, transfusions, or transplants, and highly sensitized candidates face longer waiting times and higher rejection risk; consensus testing standards have been developed to characterize HLA and non-HLA antibodies across transplant programs.

History

The recognition that histocompatibility antigens drive rejection followed early graft experiments and the discovery of the HLA system. The distinction between direct and indirect allorecognition clarified how the same antigens can provoke different responses, and the development of sensitive HLA-antibody assays transformed the assessment of sensitization and the matching of donors to recipients.

Debates

How should HLA-antibody data be interpreted for risk?

Sensitive solid-phase assays detect antibodies whose clinical significance varies, and consensus guidelines acknowledge ongoing uncertainty about thresholds, non-HLA antibodies, and how best to translate antibody data into risk assessment.

Key figures

• Peter Medawar
• Philip Halloran
• Brian Nankivell
• Brian Tait

Seminal works

• nankivell-2010
• tait-2013

Frequently asked questions

What does it mean to be sensitized before a transplant?

It means the immune system has already been primed against foreign HLA, usually by a prior pregnancy, transfusion, or transplant, so it carries memory cells and donor-specific antibodies that increase the risk of rejecting a graft bearing those antigens.

What is the difference between direct and indirect allorecognition?

In direct allorecognition, recipient T cells respond to intact donor MHC molecules on donor cells; in indirect allorecognition, they respond to donor antigens processed and presented by the recipient's own antigen-presenting cells.